Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Net Worth Advisory Group

Net Worth Advisory Group cut its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,452 shares of the pharmaceutical company’s stock after selling 27 shares during the period. Net Worth Advisory Group’s holdings in Vertex Pharmaceuticals were worth $585,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. ABC Arbitrage SA acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at about $1,510,000. Czech National Bank increased its position in shares of Vertex Pharmaceuticals by 6.2% during the fourth quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock valued at $22,486,000 after acquiring an additional 3,260 shares during the last quarter. Highview Capital Management LLC DE increased its position in shares of Vertex Pharmaceuticals by 1.8% during the fourth quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company’s stock valued at $2,324,000 after acquiring an additional 102 shares during the last quarter. Whalen Wealth Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at about $662,000. Finally, Davidson Investment Advisors increased its position in shares of Vertex Pharmaceuticals by 26.0% during the fourth quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company’s stock valued at $24,630,000 after acquiring an additional 12,631 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. StockNews.com lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $480.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Piper Sandler lowered their price objective on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Finally, Oppenheimer lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $506.70.

Insider Activity

In other news, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company’s stock, valued at $30,805,286.70. The trade was a 0.36 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 1,084 shares of company stock valued at $505,512 in the last ninety days. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Up 2.4 %

Shares of NASDAQ:VRTX opened at $500.01 on Tuesday. The company has a market capitalization of $128.40 billion, a PE ratio of -227.28, a P/E/G ratio of 2.11 and a beta of 0.41. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The firm has a 50 day simple moving average of $450.28 and a 200-day simple moving average of $461.29.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.